lobbying_activities: 831865

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
831865	9a85cbf6-6738-45e5-9e11-452a51fbe7bd	Q3	AMYLIN PHARMACEUTICALS	308536	AMYLIN PHARMACEUTICALS	2009	third_quarter	MED	Comparative Effectiveness Research Act of 2009 (H.R. 2502) Patient Centered Outcomes research Act of 2009 (S. 1213) Provisions related to comparative effectiveness reserach in S. 1679, the Affordable Health Choices Act; H.R. 3200 America's Affordable Health Choices Act of 2009; America's Healthy Futures Act of 2009	Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE		330000	0	0	2009-10-16T12:45:25-04:00